Skip to main content
Top
Published in: BMC Health Services Research 1/2016

Open Access 01-12-2016 | Research article

Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014

Authors: Joël Ladner, Marie-Hélène Besson, Etienne Audureau, Mariana Rodrigues, Joseph Saba

Published in: BMC Health Services Research | Issue 1/2016

Login to get access

Abstract

Background

Cervical cancer is the greatest cause of age-weighted years of life lost in the developing world. Human papillomavirus (HPV) infection is associated with a high proportion of cervical cancers, and HPV vaccination may help to reduce the incidence of cancer. The aim of the study was to identify barriers, obstacles, and strategies and to analyze key concerns and lessons learned with respect to the implementation of HPV vaccination program in low- and middle-income countries.

Methods

The Gardasil Access Program (GAP) is a donation program established to enable organizations and institutions in eligible low-resource countries to gain operational experience designing and implementing HPV vaccination programs. This study used an online survey to capture the experiences and insights of program managers participating in the GAP. Different factors related to HPV vaccination program management were collected. A mixed-method approach enabled the presentation of both quantitative measurements and qualitative insights.

Results

Twenty-nine programs implemented by 23 institutions in 19 low- and middle-income countries were included. Twenty programs managers (97.7 %) reported that their institution implemented sensitization strategies about vaccination prior to the launch of vaccination campaign. The most frequently reported obstacles to HPV vaccination by the program managers were erroneous perceptions of population related to the vaccine’s safety and efficacy. Reaching and maintaining follow-up with target populations were identified as challenges. Insufficient infrastructure and human resources financing and the vaccine delivery method were identified as significant health system barriers. Coupling HPV vaccination with other health interventions for mothers of targeted girls helped to increase vaccination and cervical cancer screening. The majority of program managers reported that their programs had a positive impact on national HPV vaccination policy. The majority of institutions had national and international partners that provided support for human resources, technical assistance, and training and financial support for health professionals.

Conclusion

Local organizations and institutions can implement successful HPV vaccination campaigns. Adequate and adapted planning and resources that support information sharing, sensitization, and mobilization are essential for such success. These results can inform the development of programs and policies related to HPV vaccination in low- and middle-income countries.
Literature
1.
go back to reference Ferlay J, Shin H, Baray F, Forman D, Mathers C, Parkin DM. Estimate of worldwide burden of in 2008. Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed Ferlay J, Shin H, Baray F, Forman D, Mathers C, Parkin DM. Estimate of worldwide burden of in 2008. Globocan 2008. Int J Cancer. 2010;127:2893–917.CrossRefPubMed
2.
go back to reference Oh JK, Weiderpass E. Incfection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384–92.CrossRefPubMed Oh JK, Weiderpass E. Incfection and cancer: global distribution and burden of diseases. Ann Glob Health. 2014;80:384–92.CrossRefPubMed
3.
go back to reference Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(S5):F12–23.CrossRefPubMed Forman D, de Martel C, Lacey CJ, Soerjomataram I, Lortet-Tieulent J, Bruni L, et al. Global burden of human papillomavirus and related diseases. Vaccine. 2012;30(S5):F12–23.CrossRefPubMed
4.
go back to reference Broker TR. Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities. Vaccine. 2012;30(S5):7–10. Broker TR. Global prevention and management of human papillomavirus related diseases: the pressing challenges and the compelling opportunities. Vaccine. 2012;30(S5):7–10.
5.
go back to reference Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMed Arbyn M, Castellsagué X, de Sanjosé S, Bruni L, Saraiya M, Bray F, et al. Worldwide burden of cervical cancer in 2008. Ann Oncol. 2011;22:2675–86.CrossRefPubMed
6.
go back to reference Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109:418–24.CrossRefPubMedPubMedCentral Yang BH, Bray FI, Parkin DM, Sellors JW, Zhang ZF. Cervical cancer as a priority for prevention in different world regions: an evaluation using years of life lost. Int J Cancer. 2004;109:418–24.CrossRefPubMedPubMedCentral
7.
go back to reference Bosch FX, Brokerb TR, Formanc D, Moscickid AB, Gillisone ML, Doorbarf J, et al. Comprehensive control of human papilloma infections and related diseases. Vaccine. 2013;31S:F1–F31.CrossRef Bosch FX, Brokerb TR, Formanc D, Moscickid AB, Gillisone ML, Doorbarf J, et al. Comprehensive control of human papilloma infections and related diseases. Vaccine. 2013;31S:F1–F31.CrossRef
8.
go back to reference Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.CrossRefPubMed Crosbie EJ, Einstein MH, Franceschi S, Kitchener HC. Human papillomavirus and cervical cancer. Lancet. 2013;382:889–99.CrossRefPubMed
9.
go back to reference Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.CrossRefPubMed Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ, International Agency for Research on Cancer Multicenter Cervical Cancer Study Group. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003;348:518–27.CrossRefPubMed
10.
go back to reference Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70.CrossRefPubMed Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial. Lancet. 2007;369:2161–70.CrossRefPubMed
11.
go back to reference Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–31.CrossRefPubMed Paavonen J, Naud P, Salmeron J, Wheeler CM, Chow SN, Apter D, et al. Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women. Lancet. 2009;374:301–31.CrossRefPubMed
12.
go back to reference Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit J Cancer. 2006;95:1459–66.CrossRefPubMedPubMedCentral Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen OE, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Brit J Cancer. 2006;95:1459–66.CrossRefPubMedPubMedCentral
13.
go back to reference Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine. 2009;27:38–44.CrossRefPubMed Harries J, Moodley J, Barone MA, Mall S, Sinanovic E. Preparing for HPV vaccination in South Africa: key challenges and opinions. Vaccine. 2009;27:38–44.CrossRefPubMed
14.
go back to reference Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS. HPV vaccine acceptability among Kenyan women. Vaccine. 2012;28:4864–67.CrossRef Becker-Dreps S, Otieno WA, Brewer NT, Agot K, Smith JS. HPV vaccine acceptability among Kenyan women. Vaccine. 2012;28:4864–67.CrossRef
15.
go back to reference Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.CrossRefPubMedPubMedCentral Ladner J, Besson MH, Hampshire R, Tapert L, Chirenje M, Saba J. Assessment of eight HPV vaccination programs implemented in lowest income countries. BMC Public Health. 2012;12:370.CrossRefPubMedPubMedCentral
16.
go back to reference Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health. 2014;14:670.CrossRefPubMedPubMedCentral Ladner J, Besson MH, Rodrigues M, Audureau E, Saba J. Performance of 21 HPV vaccination programs implemented in low and middle-income countries, 2009-2013. BMC Public Health. 2014;14:670.CrossRefPubMedPubMedCentral
17.
go back to reference Wigle J, Coast D, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811–7.CrossRefPubMedPubMedCentral Wigle J, Coast D, Watson-Jones D. Human papillomavirus (HPV) vaccine implementation in low and middle-income countries (LMICs): health system experiences and prospects. Vaccine. 2013;31(37):3811–7.CrossRefPubMedPubMedCentral
18.
go back to reference Steben M, Jeronimo J, Wittet S, LaMontagne SD, Ogilvie G, Jensen C, et al. Upgrading public health programs for Human Papilloamvirus Prevention and Control is possible in low – and middle-income countries. Vaccine. 2012;30S:F183–91.CrossRef Steben M, Jeronimo J, Wittet S, LaMontagne SD, Ogilvie G, Jensen C, et al. Upgrading public health programs for Human Papilloamvirus Prevention and Control is possible in low – and middle-income countries. Vaccine. 2012;30S:F183–91.CrossRef
19.
go back to reference Kane MA, Serrano B, Sanjosé S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30S:F192–200.CrossRef Kane MA, Serrano B, Sanjosé S, Wittet S. Implementation of human papillomavirus immunization in the developing world. Vaccine. 2012;30S:F192–200.CrossRef
20.
go back to reference WHO. Human papillomavirus vaccines: WHO position paper. WHO Weekly Epidemiol Record. 2009;84:117–32. WHO. Human papillomavirus vaccines: WHO position paper. WHO Weekly Epidemiol Record. 2009;84:117–32.
21.
23.
go back to reference Coleman MA, Levison J, Sangi-Haghpeykar H. HPV vaccine acceptability in Ghana, West Africa. Vaccine. 2011;29(23):3945–50.CrossRefPubMed Coleman MA, Levison J, Sangi-Haghpeykar H. HPV vaccine acceptability in Ghana, West Africa. Vaccine. 2011;29(23):3945–50.CrossRefPubMed
24.
go back to reference Woo YL, Omar SZ. Human papillomavirus vaccination in the resourced and resource-constrained world. Best Pract Res Clin Obstet Gynaecol. 2011;25(5):597–603.CrossRefPubMed Woo YL, Omar SZ. Human papillomavirus vaccination in the resourced and resource-constrained world. Best Pract Res Clin Obstet Gynaecol. 2011;25(5):597–603.CrossRefPubMed
25.
go back to reference Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries–key challenges and issues. N Engl J Med. 2007;356:1908–10.CrossRefPubMed Agosti JM, Goldie SJ. Introducing HPV vaccine in developing countries–key challenges and issues. N Engl J Med. 2007;356:1908–10.CrossRefPubMed
26.
go back to reference Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. J Bull World Health Organ. 2012;90:623–8.CrossRef Binagwaho A, Wagner CM, Gatera M, Karema C, Nutt CT, Ngabo F. Achieving high coverage in Rwanda’s national human papillomavirus vaccination programme. J Bull World Health Organ. 2012;90:623–8.CrossRef
27.
go back to reference Fregnani JH, Carvalho AL, Eluf-Neto J, Ribeiro KC, Kuil LM, Da Silva TA, et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013;8:e62647.CrossRefPubMedPubMedCentral Fregnani JH, Carvalho AL, Eluf-Neto J, Ribeiro KC, Kuil LM, Da Silva TA, et al. A school-based human papillomavirus vaccination program in Barretos, Brazil: final results of a demonstrative study. PLoS One. 2013;8:e62647.CrossRefPubMedPubMedCentral
28.
go back to reference Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Inf Dis. 2012;206:678–86.CrossRef Watson-Jones D, Baisley K, Ponsiano R, Lemme F, Remes P, Ross D, Kapiga S, Mayaud P, de Sanjosé S, Wight D, Changalucha J, Hayes R. Human papillomavirus vaccination in Tanzanian schoolgirls: cluster-randomized trial comparing 2 vaccine-delivery strategies. J Inf Dis. 2012;206:678–86.CrossRef
29.
go back to reference LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. J Bull World Health Organ. 2011;89:821–830B.CrossRef LaMontagne DS, Barge S, Le NT, Mugisha E, Penny ME, Gandhi S, et al. Human papillomavirus vaccine delivery strategies that achieved high coverage in low- and middle-income countries. J Bull World Health Organ. 2011;89:821–830B.CrossRef
30.
go back to reference Friedman AL, Oruko KO, Habel MA, Kinsey FJ, Odhiambo F, Phlips-Howards PA, et al. Preaparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Heath. 2014;14:855.CrossRef Friedman AL, Oruko KO, Habel MA, Kinsey FJ, Odhiambo F, Phlips-Howards PA, et al. Preaparing for human papillomavirus vaccine introduction in Kenya: implications from focus-group and interview discussions with caregivers and opinion leaders in Western Kenya. BMC Public Heath. 2014;14:855.CrossRef
31.
go back to reference Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school and non-school based immunization program. Vaccine. 2014;32(3):320–6.CrossRefPubMed Paul P, Fabio A. Literature review of HPV vaccine delivery strategies: considerations for school and non-school based immunization program. Vaccine. 2014;32(3):320–6.CrossRefPubMed
32.
go back to reference Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80(5):412–7.CrossRefPubMed Sankaranarayanan R. Screening for cancer in low- and middle-income countries. Ann Glob Health. 2014;80(5):412–7.CrossRefPubMed
33.
Metadata
Title
Experiences and lessons learned from 29 HPV vaccination programs implemented in 19 low and middle-income countries, 2009-2014
Authors
Joël Ladner
Marie-Hélène Besson
Etienne Audureau
Mariana Rodrigues
Joseph Saba
Publication date
01-12-2016
Publisher
BioMed Central
Published in
BMC Health Services Research / Issue 1/2016
Electronic ISSN: 1472-6963
DOI
https://doi.org/10.1186/s12913-016-1824-5

Other articles of this Issue 1/2016

BMC Health Services Research 1/2016 Go to the issue